PMID- 33121945
OWN - NLM
STAT- MEDLINE
DCOM- 20220510
LR  - 20220510
IS  - 2531-0437 (Electronic)
IS  - 2531-0429 (Linking)
VI  - 28
IP  - 3
DP  - 2022 May-Jun
TI  - Treatment interruption patterns and adverse events among patients on bedaquiline 
      containing regimen under programmatic conditions in India.
PG  - 203-209
LID - S2531-0437(20)30213-0 [pii]
LID - 10.1016/j.pulmoe.2020.09.006 [doi]
AB  - BACKGROUND: The study aimed to analyze frequency and severity of adverse events 
      (AEs) and other reasons for interruption of treatment and loss to follow up 
      (LTFU) during first six months of treatment among tuberculosis patients on 
      bedaquiline containing regimens. METHODS: This pilot exploratory observational 
      study included 275 patients enrolled consecutively over two years who received 
      bedaquiline containing regimen under programmatic conditions in India. RESULTS: 
      Among 275 patients with median age of 25 years, 86 (31.3%) patients had at least 
      one interruption with 122 total episodes of interruption. Among these 70 were 
      temporary, 35 were permanent interruptions and 17 were LTFU. The AEs due to drugs 
      were the commonest reason for interruption observed in 81.4% of temporary 
      interruption group and 97.1% of permanent interruption group. Among a total 192 
      adverse event episodes, (49.5%) were minor (grade 1-2) and (50.5%) were serious 
      (grade 3-5). Personal factors were the commonest reason for interruption observed 
      in LTFU (94.1%) group. The most common temporarily interrupted drug was 
      bedaquiline in 8.7% and permanently stopped drug was linezolid in 5% of patients. 
      CONCLUSIONS: Our study observed that drug related AEs are important risk factors 
      associated with treatment interruptions in bedaquiline containing regimens. 
      Bedaquiline is the most common temporarily interrupted drug due to AEs.
CI  - Copyright (c) 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier 
      Espana, S.L.U. All rights reserved.
FAU - Natarajan, Sekar
AU  - Natarajan S
AD  - Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis 
      and Respiratory Diseases, New Delhi 110030, India.
FAU - Singla, Rupak
AU  - Singla R
AD  - Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis 
      and Respiratory Diseases, New Delhi 110030, India. Electronic address: 
      drrupaksingla@yahoo.com.
FAU - Singla, Neeta
AU  - Singla N
AD  - Department of Epidemiology, National Institute of Tuberculosis and Respiratory 
      Diseases, New Delhi 110030, India.
FAU - Gupta, Amitesh
AU  - Gupta A
AD  - Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis 
      and Respiratory Diseases, New Delhi 110030, India.
FAU - Caminero, Jose A
AU  - Caminero JA
AD  - University Hospital of Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain.
FAU - Chakraborty, Amartya
AU  - Chakraborty A
AD  - Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis 
      and Respiratory Diseases, New Delhi 110030, India.
FAU - Kumar, Vikas
AU  - Kumar V
AD  - Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis 
      and Respiratory Diseases, New Delhi 110030, India.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201026
PL  - Spain
TA  - Pulmonology
JT  - Pulmonology
JID - 101723786
RN  - 0 (Antitubercular Agents)
RN  - 0 (Diarylquinolines)
RN  - 78846I289Y (bedaquiline)
SB  - IM
MH  - Adult
MH  - Antitubercular Agents/adverse effects
MH  - Diarylquinolines/adverse effects
MH  - Humans
MH  - India/epidemiology
MH  - *Tuberculosis, Multidrug-Resistant/drug therapy
OTO - NOTNLM
OT  - Adverse events
OT  - Anti-tubercular therapy
OT  - Bedaquiline
EDAT- 2020/10/31 06:00
MHDA- 2022/05/11 06:00
CRDT- 2020/10/30 05:36
PHST- 2020/07/25 00:00 [received]
PHST- 2020/09/23 00:00 [revised]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2022/05/11 06:00 [medline]
PHST- 2020/10/30 05:36 [entrez]
AID - S2531-0437(20)30213-0 [pii]
AID - 10.1016/j.pulmoe.2020.09.006 [doi]
PST - ppublish
SO  - Pulmonology. 2022 May-Jun;28(3):203-209. doi: 10.1016/j.pulmoe.2020.09.006. Epub 
      2020 Oct 26.